---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-21-000572"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2021-12-10T23:59:59+00:00"
generated_at: "2026-06-28T02:13:50.269698+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KORU Medical expects FY2021 revenue $23.0M-$23.2M; Q4 to show sequential growth

## Summary
- Q4 2021 expected to be the fourth consecutive quarter of positive sequential revenue growth.
- Full year 2021 revenue guidance of $23.0 million to $23.2 million.
- Domestic SCIg market expected to recover to mid-to-high single digits in 2022.
- Company expects its domestic SCIg revenue growth to be slightly ahead of the market recovery.

## SEC filing metadata
- accession: 0001161697-21-000572
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2021-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169721000572/0001161697-21-000572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169721000572/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-21-000572
- JSON: https://secwatch.observer/filing/0001161697-21-000572.json
- Plain text: https://secwatch.observer/filing/0001161697-21-000572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.